Call for sponsors & exhibitors
Venoms 2017 invites commercial sponsorship for demonstration of R&D and laboratory supplies related to field and laboratory venom research. We offer a number of highly competitive packages (examples below). If your needs are not covered by the offered packages please contact us in the first instance and we shall do our best to develop a package to suit your requirements.
- Gold: Includes a speaker slot AND an exhibition stand, plus four free passes (max 3)
- Silver: Includes a speaker slot OR an exhibition stand, plus three free passes (max 3)
- Bronze: Includes exhibition stand, plus two free passes (Max 3)
- Drinks Reception
- Delegate Bags (max 2)
- Delegate Badges (max 2)
- Event Documentation (max 2)
- Exhibition stand
For Booking Form, terms and conditions, and further information about packages and other promotional opportunities email at:
Venoms 2017 Sponsors
Bronze Sponsor and Exhibitor
MicroPharm Limited is a developer and manufacturer of therapeutic polyclonal antibodies for human and veterinary use. The Company’s core expertise lies in the raising of ovine antisera containing high levels of specific antibodies directed against antigens such as toxic molecules or viruses and the subsequent purification and modification of such antibodies to produce a range of immunotherapeutic products for clinical use. All are designed to treat acute, life-threatening emergencies, have been developed at the request of the medical profession and are required urgently either because no alternative exists or because any alternative is ineffective and/or unsafe. MicroPharm currently produces two antivenoms, ViperaTAb® for the treatment of envenomation by the European adder and EchiTAbG™ for the treatment of the carpet viper, Echis ocellatus. The Company has a number of products in development including: OraCAb for the treatment of mild and recurrent C. difficile infections, PolyCAb for the treatment of severe C. diff.; ColchiBIND for the treatment of colchicine poisoning; and ViperaVet for the treatment of dogs envenomed by one of the four medically important species of Vipera (adder) found throughout Western Europe. MicroPharm’s collaborators include Public Health England, University of Oxford, University of Leeds and the University of Edinburgh.
Publish free until 15 December 2017:
We are happy to waive the basic open access fee for manuscript submitted until 15 December 2017, as long as the manuscripts are prepared according to the published guidelines.
The Journal (ISSN: 2044-0324) will publish high-quality peer-reviewed articles addressing most aspects of therapeutic, molecular, biochemical and evolutionary research on venoms, and envenomation. The Journal aims at providing an efficient route to fast-track publication, within 10-12 weeks of manuscript submission if accepted. Furthermore, manuscripts will be made available online in their final form generally within 2-3 weeks of final acceptance.
The Journal will be primarily published online but on sufficient demand for printed version journal hard copies may also be provided to individuals and institutions.
Manuscripts in the following categories will be considered for publication: reviews, mini-reviews, research articles, research reports, research letters, clinical reports, case studies, new methods and technologies, meeting reports and commercial, patent and product news and editorials.
The Journal is currently indexed in:
- PubMed Central
- PMC Canada
- The Directory of Open Access Journals
- Google Scholar
- OPEN J-Gate
- Chemical Abstracts Service (CAS)
- Academic Search Complete (EBSCO)